Maximizing the response to Herceptin® therapy through optimal use and patient selection

Anti-Cancer Drugs

Volumn 12, Issue SUPPL. 4, 2001, Pages

  Leyland Jones, B ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

Breast cancer; Fluorescence in situ hybridization; HER2; Herceptin ; Immunohistochemistry

Indexed keywords

ANTHRACYCLINE DERIVATIVE; EPIDERMAL GROWTH FACTOR RECEPTOR; PACLITAXEL; TAMOXIFEN; TRASTUZUMAB;

BREAST CANCER; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DRUG EFFICACY; DRUG TARGETING; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; ONCOGENE NEU; PATIENT SELECTION; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT INDICATION;

EID: 0035712665     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200112004-00003     Document Type: Conference Paper

References (53)

1. Differential expression of NDF/neuregulin receptors ErbB-3 and ErbB-4 and involvement in inhibition of neuronal differentiation
2. Regulation of signal transduction and signal diversity by receptor oligomerization
3. The ErbB signaling network in embryogenesis and oncogenesis: Signal diversification through combinatorial ligand-receptor interactions
4. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling
5. ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: Implications for breast cancer
6. Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin
7. Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors
8. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu
9. Transformation mediated by the human HER-2 gene independent of epidermal growth factor receptor
10. A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor
11. The HER-2/neu oncogene in breast cancer: Prognostic factor, predictive factor, and target for therapy
12. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
13. Clinical significance of HER-2/neu oncogene amplification in primary breast cancer
14. Multivariate analysis of prognostic factors in lymph node negative breast cancer
15. A metanalysis of the interaction between HER2 and the response to endocrine therapy (ET) in metastatic breast cancer (MBC)
16. 20 Year update of the Naples GUN trial of adjuvant breast cancer therapy: Evidence of interaction between c-erb-B2 expression and tamoxifen efficacy
17. Predictive value of c-erbB-2, p53, cathepsin-D and histology of the primary tumour in metastatic breast cancer
18. p53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer
19. No significant predictive value of c-erbB-2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer
20. Lack of c-erbB-2 over-expression predicts better response to dose intensification of anthracycline-based chemotherapy in high-risk breast cancer
21. HER-2/neu in node-negative breast cancer: Prognostic significance of overexpression influenced by the presence of in situ carcinoma
22. Prognostic importance of c-erbB-2 expression in breast cancer
23. Prognostic and predictive relevance of c-erbB-2 and ras expression in node positive and negative breast cancer
24. c-erbB2 expression and benefit from adjuvant chemotherapy and radiotherapy of breast cancer
25. Surrogate endpoints in chemoprevention of breast cancer: Guidelines for evaluation of new biomarkers
26. HER-2/neu gene amplification compared with HER-2/neu protein overexpression and interobserver reproducibility in invasive breast carcinoma
27. Fluorescence in situ hybridization (FISH) for detection of HER2-neu amplification in breast cancer: A multicenter portability study
28. Experts debate value of HER2 testing methods
29. HER-2/neu protein expression in breast cancer evaluated by immunohistochemistry: A study of interlaboratory agreement
30. Genetic alterations in ERBB2-amplified breast carcinomas
31. Determination of Her-2/neu status in breast carcinoma: Comparative analysis of immunohistochemistry and fluorescent in situ hybridisation
32. Laboratory assessment of the status of Her-2/neu protein and oncogene in breast cancer specimens: Comparison of immunohistochemistry assay with fluorescence in situ hybridisation
33. The hyperplasia-to-carcinoma sequence in the breast: Immunohistochemical-histologic correlations
34. Assessment of HER-2/neu overexpression in primary breast cancers and their metastatic lesions: An immunohistochemical study
35. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer
36. Initial report of the SWOG biological correlative study of c-erbB-2 expression as a predictor of outcome in a trial comparing adjuvant CAFT with Tamoxifen (T) alone
37. erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer
38. Efficacy and safety of Herceptin® in women with metastatic breast cancer: Results from pivotal clinical studies
39. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease
40. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
41. First-line, non-hormonal, treatment of women with HER2 overexpressing metastatic breast cancer with Herceptin (trastuzumab, humanized anti-HER2 antibody)
42. The concordance between the clinical trials assay (CTA) and fluorescence in situ hybridization (FISH) in the Herceptin pivotal trials
43. Herceptin (H) and navelbine (V) for HER2-positive metastatic breast cancer: A phase II study
44. Final report: Weekly (W) Herceptin (H) and taxol (T) for metastatic breast cancer (MBC): Analysis of efficacy by HER2 immunophenotype [immunohistochemistry (IHC)] and gene amplification [fluorescent in-situ hybridisation (FISH)]
45. Pharmacologic insights into the future of Herceptin®
46. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer
47. Phase III study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment
48. Pharmacokinetics of Herceptin administered with paclitaxel every 3 weeks
49. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs
50. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin)
51. Mechanism of action of anti-HER2 monoclonal antibodies
52. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers
53. Treatment beyond progression in the Herceptin pivotal combination chemotherapy trial